## IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: DIET DRUGS (PHENTERMINE/ FENFLURAMINE/DEXFENFLURAMINE) PRODUCTS LIABILITY LITIGATION	MDL NO. 1203
THIS DOCUMENT RELATES TO:	
JAMIE D. CHEEK	
v. ()	
WYETH, et al.	CIVIL ACTION NO. 11-20001
) VALARIE FARMER )	
v. )	CIVII ACTION
() WYETH PHARMACEUTICALS INC., et al. ) )	CIVIL ACTION NO. 99-20593

## PRETRIAL ORDER NO. 8933

AND NOW, this **30th** day of August, 2012, for the reasons set forth in the accompanying Memorandum, it is hereby ORDERED that:

(1) the motion of defendant Wyeth, LLC to enjoin plaintiff Valarie Farmer under PTO Nos. 1415 and 2383 from prosecuting her action in <u>Farmer v. Wyeth Pharmaceuticals, Inc.,</u> <u>et al.</u>, July Term 2011, No. 01174, in the Court of Common Pleas of Philadelphia County, Pennsylvania is DENIED;

(2) the motion of defendant Wyeth, LLC to enjoin plaintiff Jamie D. Cheek under PTO Nos. 1415 and 2383 from prosecuting her action in <u>Cheek v. Wyeth, et al.</u>, No. 11-54, in the United States District Court for the District of South Carolina is DENIED; and

(3) the motion of defendant Wyeth, LLC to exclude the expert testimony on the issue of causation of primary pulmonary hypertension proffered by plaintiff Jamie D. Cheek in <u>Cheek v.</u> <u>Wyeth, et al.</u>, No. 11-54, in the United States District Court for the District of South Carolina is DENIED.

BY THE COURT: